This player's pipeline should keep growth going over the long run.

These biotech companies have catalysts ahead.

Biotech hot picks spotlight Xenon, United Therapeutics and Axsome as Phase III data and FDA decisions approach.

Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...

Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has three promising candidates in early development as well as its only ...

2026 could be a big year for this company.

Biotech stocks are gaining momentum as weight-loss drugs, pipeline depth and clinical data drive renewed growth optimism.

Raise large amounts of capital with an initial public offering, burn cash while navigating clinical trials, then submit a new ...

The words “sure-fire” and biotechnology stocks rarely go together. This is a sector of the stock market that carries higher-than-average risk. The success of these companies depends on clinical trial ...

Recent developments in the Canadian market, such as a decline in unemployment and easing inflation, suggest a cautiously optimistic economic outlook. In this context, penny stocks—typically ...